# Aimisen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aimisen

- Industry: Healthcare Specialists
- Headquarters: Wuhan, China
- Website: www.ammulifetech.com
- Total disclosed funding: $31M
- Latest round: Series C (Apr 28, 2022)
- Investors on record: 8

## About

Established in 2015 and based in Wuhan, China, Aimisen operates as a tumor early screening detection technology developer. The company was identified by "the national high technology enterprise 2020". The company completed round B financing from the golden and he capital collar in February 2021. Mr. Lianglu Zhang is the founder of the company.

The company provides tumor detection technology for patients with colorectal cancer and cervical cancer. The business of the company includes IVD R & D, manufacturing, marketing, and medical testing. The company focuses on non-invasive screening and early detection products development and testing services for high incident malignant tumors. The company's product includes IColocomf® and ICON®series. The company adopts epigenetics, nanomaterials, bioinformatics, clinical big data and artificial intelligence.

The company will put the funding towards market expansion, product R&D, registration and clinical trial application in series C funding.

## Funding rounds

- Series C, Apr 28, 2022, $15M — CCB International, Wuhan Hi-tech Holding Group, Herui Venture Capital
- Series B, Feb 2, 2021, $15M — Guangdong Hybribio Biotech, Jinyuan Kuntong Equity Investment Management, Changjiang Securities
- Angel, Nov 11, 2016 — Guanggu Rencai Fund, Dongke Chuangxing Venture Capital

## Investors

- Guanggu Rencai Fund (https://capitalatlas.ai/funds/guanggu-rencai-fund) — Angel
- Dongke Chuangxing Venture Capital — Angel
- Guangdong Hybribio Biotech — Series B
- Jinyuan Kuntong Equity Investment Management (https://capitalatlas.ai/funds/jinyuan-kuntong-equity-investment-management) — Series B
- Changjiang Securities — Series B
- CCB International (https://capitalatlas.ai/funds/ccb-international) — Series C
- Wuhan Hi-tech Holding Group — Series C
- Herui Venture Capital (https://capitalatlas.ai/funds/herui-venture-capital) — Series C